| 左武剑,李新天.仅委托生产的药品上市许可持有人质量管理的现状调研分析[J].中国药事,2024,38(7):745-751 |
| 仅委托生产的药品上市许可持有人质量管理的现状调研分析 |
| Investigation and Analysis on Quality Management of MAH Only CommissioningProduction |
| |
| DOI：10.16153/j.1002-7777.2024.07.003 |
| 中文关键词: 药品上市许可持有人 委托生产 质量管理 现状调研 分析与建议 |
| 英文关键词: marketing authorization holder commission production quality management current situationinvestigation analysis and suggestion |
| 基金项目:江苏省药品监管科学科研计划项目（编号 202301） |
|
| 摘要点击次数: 0 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的：药品上市许可持有人制度实施后，仅委托生产的持有人数量不断增加，带来潜在的风险隐患。本研究旨在对仅委托生产的药品上市许可持有人完善质量管理体系和监管部门制定举措提供参考。方法：以江苏省内企业为研究对象，开展仅委托生产的药品上市许可持有人质量管理现状调查，发现其质量管理方面存在的问题，分析原因并提出建议。结果：仅委托生产的药品上市许可持有人基础相对薄弱，质量管理存在质量安全主体责任落实不到位、质量和风险管控能力不足等问题，其原因主要为质量意识薄弱、合作匹配不易、主体地位弱势、体系衔接困难等。结论：仅委托生产的药品上市许可持有人应积极履行质量安全主体责任，药品监管部门可以采取创新监管方式、强化行政指导等措施，不断完善质量管理体系，优化监管举措，保障药品质量和用药安全。 |
| 英文摘要: |
| Objective: The number of marketing authorization holders (MAHs) only commissioning productionis constantly increasing after the implementation of the MAH system, which brings risks. The aim of the researchis to provide workable proposals for the quality management of MAH and drug regulatory anthorities. Methods:Taking the enterprises in Jiangsu province as the research object, the quality management status of MAH onlycommissioning drug production was investigated, the existing problems in quality management were found,the causes were analyzed and suggestions were put forward. Results: There were some unique problems suchas inadequate implementation of quality and safety main responsibilities, insufficient quality and risk controlcapabilities in the quality management system of the MAH, which were mainly caused by weak quality awareness,diffi culty cooperation and matching, weak subject status, and diffi culty in quality system connection. Conclusion:MAH only commissioning drugs should actively fulfi ll the main responsibicity of quality and safety, and drugregulatory authorities can take measures such as inovating regulatory methods and strengthening adminiatrativeguidance to continuously improve the quality management system and optimize regulatory measures to ensuredrug quality and drug safety. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |